BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17629666)

  • 1. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
    Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S
    J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid switching between transdermal fentanyl and methadone in cancer patients.
    Mercadante S; Ferrera P; Villari P; Casuccio A
    J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
    Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
    Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of cancer-related pain with transdermal fentanyl.
    Leelanuntakit S
    J Med Assoc Thai; 1996 Jun; 79(6):341-6. PubMed ID: 8855606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.
    Apolone G; Corli O; Negri E; Mangano S; Montanari M; Greco MT; ; Apolone G; Bertetto O; Caraceni A; Corli O; De Conno F; Labianca R; Maltoni M; Nicora Maria F; Torri V; Zucco F
    Clin J Pain; 2009 Oct; 25(8):671-82. PubMed ID: 19920716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
    Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
    Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
    J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved cancer pain treatment using combined fentanyl-TTS and tramadol.
    Marinangeli F; Ciccozzi A; Aloisio L; Colangeli A; Paladini A; Bajocco C; Coaccioli S; Varrassi G
    Pain Pract; 2007 Dec; 7(4):307-12. PubMed ID: 17986161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
    van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
    Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of safety and efficacy of transdermal therapeutic system-fentanyl in adult patients with gynecological cancer-related pain.
    Lorvidhaya V; Katanyoo K; Srisomboon J; Suprapaphorn P; Cheewakriangkrai C
    J Med Assoc Thai; 2004 Mar; 87(3):319-25. PubMed ID: 15117050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
    Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
    J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transdermal route as an alternative to oral administration of opioids in cancer pain].
    Burza M; Ginobbi P; Fusco G; Laurenzi L; Tirelli W; Arcuri E
    Clin Ter; 1998; 149(4):277-80. PubMed ID: 9866889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl].
    Fujimoto M; Sakuyama T; Mizutani Y; Kuroda T; Yanaga K
    Gan To Kagaku Ryoho; 2004 Dec; 31 Suppl 2():190-3. PubMed ID: 15645768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain.
    Otis J; Rothman M
    Curr Med Res Opin; 2006 Aug; 22(8):1493-501. PubMed ID: 16870074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.